Aventis Pharmaceuticals Inc.

Aventis Pharma Limited

Rhone Poulenc Rorer

Paul Joseph Cox

Andrew David Morley

Tahir Nadeem Majid

Shelley Amendola

Stephanie Deprets

Christopher D Edlin

Michael L Edwards

Brian L Pedgrift

Herve Bouchard

David John Aldous

Charles J Gardner

Timothy A Gillespy

Justine Yeun Quai Lai

Stevan Wakefield Djuric

John R Regan

Frank Halley

Daniel Gerard McGarry

Gregory Bernard Poli

Peter Charles Astles

Kevin Joseph Moriarty

Christopher Hulme

Rose Mappilakunnel Mathew

Fu-Chih Huang

Didier Babin

John Charles Reader

Dominique Damour

Conception Nemecek

Francois Clerc

Michael Cherry

Dorothea Kominos

Chantal Carrez

Laurence Gauzy

Nawaz Mohammed Khan

Olivier Houille

Alain Le-Brun

Lloyd J Payne

Daniel N A Bezard

Shelley Bower

Neil Victor Harris

Iain M McLay

Bernard Baudoin

Barry Porter

Paul Robert Eastwood

David Edward Clark

Alan John Collis

Christoper David Edlin

Stephanie D Deprets

Justine Y Q Lai

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Benzimidazoles

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and pharmaceutically acceptable salts of the compounds of formula (I) and N-oxides thereof, Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmnaceutical compositions comprising compoundS of formula (I), their phatmaceUtical use and methods for their preparation.

Substituted azabicyclic compounds

Compounds of the formula and N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.

Pyrrolopyrimidines

Chemical compositions containing physiologically active compounds of general formula (I): wherein Ris aryl or heteroaryl; Rrepresents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -ZR, &#x2014;C(&#x2550;O)&#x2014;NYY, &#x2014;COR, &#x2014;NYY, &#x2014;N(R)&#x2014;C(&#x2550;O)&#x2014;R, &#x2014;N(R)&#x2014;C(&#x2550;O)&#x2014;NYY, &#x2014;N(R)&#x2014;C(&#x2550;O)&#x2014;OR, &#x2014;N(R)&#x2014;SO&#x2014;R, &#x2014;N(R)&#x2014;SO&#x2014;NYYand one or more halogen atoms; Rrepresents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, &#x2014;C(&#x2550;O)&#x2014;ORor &#x2014;C(&#x2550;O)&#x2014;NYY; and Xrepresents N, CH, C-halo, C&#x2014;CN, C&#x2014;R, C&#x2014;NYY, C&#x2014;OH, C-ZR, C&#x2014;C(&#x2550;O)&#x2014;OR, C&#x2014;C(&#x2550;O)&#x2014;NYY, C&#x2014;N(R)&#x2014;C(&#x2550;O)&#x2014;R, C&#x2014;SO&#x2014;NYY, C&#x2014;N(R)&#x2014;SO&#x2014;R, C-alkenyl, C-alkynyl or C&#x2014;NO; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.

Azaindoles

The invention is directed to physiologically active compounds of general formula (I):and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

The invention is directed to physiologically active compounds of the general formula (Ix)and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Substituted anilides

This invention is directed to certain physiologically active compounds of formula (I)

Growing community of inventors

Flemington, NJ, United States of America

Paul Joseph Cox